Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial...
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
About this item
Full title
Author / Creator
Publisher
New York, NY: Mosby, Inc
Journal title
Language
English
Formats
Publication information
Publisher
New York, NY: Mosby, Inc
Subjects
More information
Scope and Contents
Contents
Background Vitamin K antagonists have been the standard oral antithrombotic used for more than a half century for prevention and treatment of thromboembolism. Their limitations include multiple food and drug interactions and need for frequent monitoring and dose adjustments. Edoxaban is a selective and direct factor Xa inhibitor that may provide ef...
Alternative Titles
Full title
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_757460034
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_757460034
Other Identifiers
ISSN
0002-8703
E-ISSN
1097-6744
DOI
10.1016/j.ahj.2010.06.042
